General Background of YB-1
==========================

YB-1 is an oncogenic transcription/translation factor that leads to the development of cancer. It controls the oncogenome by shuttling between the cytoplasm and the nucleus. In the cytoplasm, YB-1 acts as a translation factor that regulates the expression of oncogenes by transporting mRNA to polysomes ([@b124-tog-2-2007-049]). It is also intimately involved in the translational machinery ([@b4-tog-2-2007-049]) where YB-1 governs whether or not oncogenic mRNA's will ultimately be translated ([@b36-tog-2-2007-049]). Upon nuclear translocation, YB-1 regulates transcription by binding directly to genes involved in tumor growth and drug resistance. YB-1 also associates with other transcription factors, such as p53 ([@b97-tog-2-2007-049]), AP-1 (Lasham et al. 2000), Smad 3 ([@b52-tog-2-2007-049]) and p300 ([@b52-tog-2-2007-049]) to indirectly regulate gene expression. The nuclear functions of YB-1 also include a role in DNA replication (En-Nia et al. 2004), repair (Marenstein et al. 2001) and mRNA transport into the cytoplasm ([@b124-tog-2-2007-049]). Thus, YB-1 is involved in many aspects of gene expression control that lead to tumor cell growth and drug resistance ([Figure 1](#f1-tog-2-2007-049){ref-type="fig"}). YB-1 was first isolated as a transcription factor that bound to the promoter of the major histocompatibility complex class II (MHC Class II) suggesting that it could theoretically obscure immune cells from destroying cancer cells. At the same time, another group identified a DNA binding protein that interacted with the epidermal growth factor (EGFR) enhancer and Her-2 promoter ([@b109-tog-2-2007-049]). Soon after, YB-1/DbpB was reported to bind to CT-rich elements in the *C-myc* promoter ([@b73-tog-2-2007-049]). From the early studies on YB-1, one can envisage that this transcription factor could facilitate the development of cancer in part by escaping immunosurveillance and at the same time inducing pro-survival pathways such as EGFR, Her-2 and c-Myc.

At the protein level, YB-1 consists of three domains; a non-conserved variable N-terminal domain, a highly conserved cold-shock domain (CSD), and a C-terminal domain (CTD) ([@b71-tog-2-2007-049]) ([Figure 1](#f1-tog-2-2007-049){ref-type="fig"}). The N-terminal domain, which is rich in alanine and proline residues, is thought to be involved in transactivation ([@b71-tog-2-2007-049]). The CSD binds oligonucleotides including RNA, double stranded DNA, and single stranded DNA ([@b29-tog-2-2007-049]; [@b50-tog-2-2007-049]; [@b74-tog-2-2007-049]; [@b16-tog-2-2007-049]; [@b78-tog-2-2007-049]). It also contains two conserved RNP (ribonucleoprotein particles) motifs ([@b47-tog-2-2007-049]) thought to be important in the transport and translational control of mRNA. The CTD of YB-1 contains alternating regions of basic and acidic residues, termed charged zipper or B/A repeats, and is suggested to mediate protein-protein interactions ([@b136-tog-2-2007-049]; [@b16-tog-2-2007-049]; [@b134-tog-2-2007-049]; [@b87-tog-2-2007-049]). Proteins shown to interact with YB-1 include proliferating cell nuclear antigen (PCNA), MutS homologue 2 (MSH2), and DNA polymerase δ ([@b59-tog-2-2007-049]; [@b41-tog-2-2007-049]). The alternating blocks of basic and acidic residues are also common features of proteins that bind to ribonucleoprotein complexes to shuttle between the cytoplasm and the nucleus ([@b105-tog-2-2007-049]). Indeed, noncanonical nuclear localization signals (NLS) and a cytoplasmic retention site (CRS) were identified in the CTD to control YB-1 cellular localization ([@b6-tog-2-2007-049]). Reportedly the CSD also co-operates with the CTD to facilitate nuclear trafficking (Jurchott et al. 2003). These studies contribute to our overall understanding of how the structure of YB-1 dictates the function. It is now known that RNA/DNA binding ([@b69-tog-2-2007-049]) and protein:protein interactions are controlled by specific YB-1 domains ([Figure 1](#f1-tog-2-2007-049){ref-type="fig"}; [@b71-tog-2-2007-049]; [@b104-tog-2-2007-049]; [@b121-tog-2-2007-049]).

How does YB-1 play a role in cancer?
====================================

YB-1 has been shown to be associated with many malignancies including colorectal carcinomas ([@b120-tog-2-2007-049]), prostate cancer ([@b42-tog-2-2007-049]), osteosarcoma ([@b94-tog-2-2007-049]), ovarian serous adenocarcinoma ([@b66-tog-2-2007-049]; [@b144-tog-2-2007-049]), lung cancer ([@b118-tog-2-2007-049]; [@b49-tog-2-2007-049]), synovial sarcoma ([@b93-tog-2-2007-049]) and breast cancer ([@b7-tog-2-2007-049]; [@b61-tog-2-2007-049]; [@b108-tog-2-2007-049]; [@b55-tog-2-2007-049]; [@b142-tog-2-2007-049]). Much less is known about the role of YB-1 in childhood cancers. The first study of its kind will be published this year showing that YB-1 is a feature of pediatric glioblastoma multiforme (GBM) ([@b38-tog-2-2007-049]). This was discovered initially by comparing gene expression profiles from pediatric and adult GBM. In this study, we determined that YB-1 is highly expressed in pediatric GBM whereas the frequency of this in adult GBM was far less. Our laboratory has also gone on to study a pediatric tumor tissue microarray that includes multiple solid tumors types from children. We have further identified very high levels of YB-1 in 44% of Ewings sarcomas (n = 12/21 cases, unpublished). Interestingly YB-1 is exclusively expressed in the nucleus (unpublished). Given the expression of YB-1 in so many tumor types it seems obvious that it must play an important role in the development of cancer. It has been shown in a transgenic mouse model that YB-1 induces mammary tumor formation with 100% genetic penetrance ([@b12-tog-2-2007-049]). Close examination of the mouse mammary tumors revealed a high content of binucleate cells, most of which were tetraploid. There was also a high degree of chromosomal instability. It was speculated that YB-1 may promote breast tumor formation and/or growth by accelerating cell cycle progression and escaping DNA damage check points ([@b12-tog-2-2007-049]). Whether or not YB-1 plays a causative role in the development of other types of cancer is unknown at this time.

Independent of whether YB-1 is instrumental in the development of cancer it certainly plays an important role in mediating the growth of malignant cells. The first direct evidence for a role of YB-1 in cell proliferation came from gene knock down experiments where the loss of one allele in the chicken lymphocytic cells inhibited growth by \>70% ([@b135-tog-2-2007-049]). The growth and survival of cancer cells are also dependent upon YB-1. For example, melanoma, adenocarcinoma, hepatoma, fibrosarcoma and colon cancer cells die when YB-1 is knocked out with antisense ([@b135-tog-2-2007-049]). Recently, we used siRNAs to inhibit the expression of YB-1, resulting in a 48% reduction in breast cell growth in monolayer ([@b142-tog-2-2007-049]) and under anchorage independent conditions (unpublished). Furthermore, our lab demonstrated that YB-1, but not the mutant YB-1 in which S102 is changed to alanine (YB-1A102), enhances the growth of breast cancer cells both in monolayer and anchorage-independent conditions ([@b133-tog-2-2007-049]). It was further revealed that YB-1 co-expresses with two epidermal growth factor receptors, EGFR and Her-2, and that YB-1, but not YB-1A102, up-regulates the expression of these receptors. Since EGFR and Her-2 are two important markers for breast carcinoma, it was proposed that YB-1 promotes breast cancer growth by stimulating the expression of EGFR and Her-2 ([@b142-tog-2-2007-049]). In further support of this observation, the expression of YB-1 in immortalized breast epithelial cells causes enhanced cell growth, which correlates with the induction of EGFR ([@b13-tog-2-2007-049]). It can therefore be generally stated that YB-1 is essential for the growth of breast cancer cells. In further support of this, it was discovered by several groups that YB-1 is over-expressed in breast carcinoma and it is associated with tumor aggressiveness, relapse and poor survival ([@b7-tog-2-2007-049]; [@b108-tog-2-2007-049]; [@b61-tog-2-2007-049], [@b142-tog-2-2007-049]).

Much of the work on YB-1 in cancer is centered around its role as a transcription factor while less is known about how this factor affects translation. As a transcription factor, YB-1 binds to the inverted CCAAT element in the Y-box ([@b29-tog-2-2007-049]; [@b44-tog-2-2007-049]; [@b91-tog-2-2007-049]; [@b65-tog-2-2007-049]). YB-1 is also able to recognize Y-boxes without the consensus inverted CCAAT box ([@b82-tog-2-2007-049]; [@b52-tog-2-2007-049]; [@b76-tog-2-2007-049]), and sequences flanking the Y-box have been suggested to contribute to YB-1:DNA interactions ([@b29-tog-2-2007-049]; [@b91-tog-2-2007-049]). YB-1 up-regulates the transcription of *CYCLIN* A ([@b65-tog-2-2007-049]), *CYCLIN B1* ([@b65-tog-2-2007-049]), *TOPOISOMERASE II* α ([@b120-tog-2-2007-049]), and *DNA POLYMERASE* α ([@b35-tog-2-2007-049]), implying that YB-1 enhances cell growth possibly by promoting both cell cycle progression and DNA replication. It was further demonstrated by Swamynathan et al. that cells with targeted disruption of one allele of YB-1 displayed defects in cell cycle and reduction in cell growth ([@b135-tog-2-2007-049]). A role for YB-1 in DNA replication, on the other hand, is not as clear. Although it has been suggested that YB-1 interacts with the proliferating cell nuclear antigen (PCNA; [@b59-tog-2-2007-049]) and DNA polymerase δ ([@b41-tog-2-2007-049]), whether YB-1 is part of the DNA replication holoenzyme needs further investigation.

Due to its role in cell growth, YB-1 is implicated in cancer pathogenesis. In addition to inducing the growth-promoting genes described above, YB-1 was shown to control the expression of phosphatase PTP1B ([@b40-tog-2-2007-049]), matrix metalloproteinase-2 (MMP-2) ([@b82-tog-2-2007-049]; [@b83-tog-2-2007-049]), matrix metalloproteinase-12 (MMP-12) ([@b110-tog-2-2007-049]), collagen α 1(I) ([@b91-tog-2-2007-049]), and collagen α 2(I) ([@b52-tog-2-2007-049]; [@b32-tog-2-2007-049]), all of which are involved in cell adhesion, motility, invasion and thus metastasis. The transcriptional activity of YB-1 on MMP-2 was demonstrated to be dependent on the interaction with two other transcription factors, namely the activating protein-2 (AP-2) and p53 ([@b83-tog-2-2007-049]). Furthermore, YB-1 promotes the expression of several players in drug resistance, including p-glycoprotein encoded by the multi-drug resistance gene (MDR1) ([@b44-tog-2-2007-049]; [@b128-tog-2-2007-049]), multi-drug resistance-related protein-1 (MRP 1) ([@b128-tog-2-2007-049]), as well as the major vault protein (MVP) ([@b127-tog-2-2007-049]). The ability to regulate genes related to metastasis and drug resistance suggests that YB-1 may be a marker for tumor aggressiveness and may predict poor response to chemotherapies.

Does the expression of YB-1 change the way cancer cells respond to therapy?
===========================================================================

Overcoming drug resistance is key in treatment of many chronic diseases including malignancies. The ATP-binding cassette (ABC) transporters are a family of membrane proteins that are responsible for efflux of a variety of compounds out of the cell in an energy dependent manner. Although this mechanism is protective in terms of reducing toxins within cells, it also causes drug resistance by eliminating clinically useful drugs. Multidrug resistance-1 (MDR-1) gene codes for p-glycoprotein (an ABC transporter) believed to be responsible for multidrug resistance in cells ([@b23-tog-2-2007-049]). The MDR-1 gene is often over-expressed after chemotherapy, either via gene activation or gene amplification, in various human tumors. The MDR-1 gene over-expression is observed in various malignancies including breast cancer, ovarian cancer, osteosarcoma, and synovial sarcoma. YB-1 is involved in MDR-1 gene activation in response to genotoxic stress ([@b96-tog-2-2007-049]). Antisense to YB-1 sensitizes cells to cisplatin, mitomycin C and UV radiation, but not to vincristine, doxorubicin, campothecin, or etoposide ([@b95-tog-2-2007-049]). Moreover, mouse embryonic stem cells expressing heterozygous YB-1 are hypersensitive to cisplatin and mitomycin C, suggesting that YB-1 has a protective capacity against cytotoxic effects of DNA damaging agents, demonstrating the involvement of YB-1 in drug resistance ([@b119-tog-2-2007-049]). Furthermore, YB-1 binds to cisplatin-damaged DNA and interacts with PCNA, a protein involved in DNA repair. Thus YB-1 may be important in DNA repair or in directing the response of the cells to DNA damage. It has also been proposed that cisplatin may activate MDR1 gene expression by stimulating YB-1 to gain access to the MDR-1 promoter ([@b59-tog-2-2007-049]). YB-1 is therefore considered to be important in mediating drug resistance.

Several studies demonstrate that the expression of YB-1 is particularly prevalent in hormone-dependent cancers such as those arising in the breast, ovary and prostate. A common theme between these studies is that YB-1 is notably found in the nuclear compartment and that it promotes drug resistance presumably by inducing genes that render cancer cells resistant to therapy. YB-1 positively regulates transcription of MDR-1, and in a number of malignancies YB-1 levels are closely associated with the expression of p-glycoprotein. In breast cancer, nuclear localization of YB-1 is associated with MDR-1 gene expression and drug resistance, while cytoplasmic localization of YB-1 is associated with drug sensitivity ([@b7-tog-2-2007-049]). The chemotherapy failure in breast cancer patients is associated with resistance, either acquired or intrinsic (primary resistance), of tumor cells. Furthermore, high levels of YB-1 protein expression are significantly associated with poor patient outcome. Breast cancer patients receiving post-operative chemotherapy with a high YB-1 expression had a 66% relapse rate after 5 years, compared to 0% relapse rate in those with low YB-1 expression ([@b61-tog-2-2007-049]). Therefore, early identification of patients at high risk for relapse is important and it would be of great clinical significance to have markers to predict which patients would respond to chemotherapy (i.e. chemosensitivity markers). In addition, aggressive breast cancer tumors that are both ER negative and lymph node positive are associated with high YB-1 expression. Breast cancer patients that were on a chemotherapy regimen containing anthracycline, a p-glycoprotein substrate, developed recurrence and had higher YB-1 levels compared to those treated with regimens containing non- p-glycoprotein substrate regimens (cyclophosphamide/methotrexate/5-Fluorouracil). Therefore YB-1 expression aside from being a marker of chemoresistance, may be clinically significant in aiding selection of the appropriate chemotherapy regimen ([@b55-tog-2-2007-049]). In serous ovarian carcinomas, the expression of YB-1 in the nucleus is a useful prognostic marker as the five-year survival curve for patients with positive nuclear YB-1 tumors was significantly worse than those with YB-1 negative tumors ([@b66-tog-2-2007-049]). Co-expression of YB-1 and p-glycoprotein may reflect the resistance of ovarian cancer to chemotherapy and account for its unfavorable prognosis ([@b56-tog-2-2007-049]). Cisplatin resistant ovarian cancer cells have much higher YB-1 nuclear expression compared to drug sensitive parental cells. Therefore the expression of nuclear YB-1 is associated with acquired cisplatin resistance and might be used as a predictive marker for determining which patients with recurrent or persistent ovarian cancers will benefit from cisplatin based chemotherapy ([@b144-tog-2-2007-049]). Finally, in the prostate, YB-1 over-expression, as well as, increased in p-glycoprotein levels is observed during malignant transformation. In addition to drug resistance, increased p-glycoprotein activity leads to lower androgen levels in the tumor cells leading to an adaptive response and androgen independence ([@b42-tog-2-2007-049]). YB-1 may therefore be of prognostic value in prostate cancer.

Similar to the examples cited in hormone-dependent malignancies, YB-1 has also been linked to drug resistance in colon, lung, muscle and thyroid cancers. Nuclear YB-1 expression in non-small cell lung cancer and squamous cell carcinoma correlated significantly with tumor size, lymph node metastasis, stage of disease, and poor prognosis compared to those with cytoplasmic YB-1 expression. This correlation was not observed in adenocarcinomas of the lung ([@b118-tog-2-2007-049]). YB-1 has been shown to be elevated in colorectal carcinomas, but there is no correlation with MDR-1 expression ([@b120-tog-2-2007-049]). In synovial sarcoma, nuclear expression of YB-1 protein is associated with p-glycoprotein expression, and is an independent prognostic factor ([@b93-tog-2-2007-049]). Also, YB-1 may be a prognostic marker for multidrug resistance in osteosarcoma as its nuclear localization is associated with the expression of p-glycoprotein ([@b94-tog-2-2007-049]). In contrast to the abovementioned carcinomas with predominantly nuclear YB-1 over-expression, it is mainly located in the cytoplasm of anaplastic thyroid carcinoma. This suggests a role in transformation by regulating translation as well as transcription ([@b60-tog-2-2007-049]). Interestingly, anaplastic carcinomas also more frequently express the p-glycoprotein compared to differentiated carcinomas of the thyroid and benign adenomas, once again signifying the association between YB-1and MDR-1 expression ([@b130-tog-2-2007-049]; [@b131-tog-2-2007-049]). Collectively these studies indicate that YB-1 is likely to be very important in promoting the expression of a milieu of genes involved in drug resistance which could explain why its expression is so firmly associated with relapse and poor overall survival rates.

Why is YB-1 over-expressed in cancer?
=====================================

From the onset it should be stated that little is known about the mechanism(s) behind the over-expression of YB-1 in cancer. One could postulate that this occurs due to gene amplification. YB-1 resides on chromosome 1p34, and genetic alterations in 1p are found in lung, colon and breast ([@b51-tog-2-2007-049]). Upon closer inspection, fine mapping of 1p34 from lung cancer cell lines reveals that the region commonly amplified is at 1p34.2, the loci for *myc* ([@b68-tog-2-2007-049]) whereas YB-1 resides at 1p34.1. Similarly, amplifications are reported in lung cancer at 1p34.3 to 1p34.4 ([@b51-tog-2-2007-049]) but again not at the YB-1 loci. Likewise, we find that YB-1 is not amplified in breast cancers using comparative genomic hybridization (submitted). Furthermore, there is no evidence for gene amplification at 1p34 (Shadeo et al. 2005) from breast cancer cell lines that are known to express YB-1. Thus, while YB-1 is highly expressed in breast cancer it does not appear to be due to a gain in copy number. Alternatively, it could be due to transcriptional activation.

To date, very few studies have addressed the transcriptional regulation of the YB-1 promoter. In one report, multiple E-boxes and GF-boxes on the *YB-1* gene promoter are bound by c-Myc, which interacts with p73 to regulate YB-1 expression ([@b139-tog-2-2007-049]). To further explore potential regulatory elements on the YB-1 promoter we retrieved the first -2kB from the UCSC genome browser (<http://genome.ucsc.edu/>; YBX1 RefSeq NM 004559) and analyzed it by CONSITE (<http://mordor.cgb.ki.se/cgi-bin/CONSITE/consite>). A particular strength of using CONSITE to predict regulatory elements is that it integrates promoters across species to generate the most plausible candidates ([@b111-tog-2-2007-049]). Because YB-1 is so highly conserved across species, we felt this was a good approach. When the YB-1 promoter (−2kB region) is compared across species, with a 90% stringency cut-off, multiple binding sites are revealed such as AML-1, rel and hunchback. If only the human YB-1 promoter is taken into consideration, it appears that there are several candidates worthy of mention including MAX, ARNT, and FOS using 90% as the cut-off. When the stringency is increased to 100% only N-Myc and Snail are predicted regulatory sites on the *YB-1* promoter ([Figure 2B](#f2-tog-2-2007-049){ref-type="fig"}). All three members of the Myc family, C, N and L-Myc, play important roles in the regulation of cell growth through their action as transcriptional activators when dimerized with MAX. The Myc:MAX complex binds to E-boxes (CA(T/C)GTG) in the promoter of many genes ([@b24-tog-2-2007-049]; [@b141-tog-2-2007-049]). It is thought that N-Myc and C-Myc are redundant proteins differing only in the pattern of expression. *C-myc* is expressed in both embryonic and adult tissues whereas *N-myc* expression is predominantly restricted to embryonic tissues that do not express *c-myc* ([@b57-tog-2-2007-049]). Following this, a wide range of cancers such as Burkitt's lymphoma ([@b28-tog-2-2007-049]), prostate cancer ([@b39-tog-2-2007-049]) and breast cancer ([@b107-tog-2-2007-049]) involve *c-myc* dysregulation whether this is through constitutive expression following chromosomal translocation, amplification or over-expression. In contrast, N-Myc is predominantly associated with neuroblastoma and other tumors of embryonal origin ([@b114-tog-2-2007-049]; [@b57-tog-2-2007-049]) with approximately 25% of the former presenting with over-expressed or amplified *N-myc*. Increased copy number is particularly associated with poor prognosis and rapid tumor progression ([@b18-tog-2-2007-049]; [@b17-tog-2-2007-049]). In addition to Myc, Snail may also regulate the expression of YB-1 based on our analyses. Snail belongs to a superfamily of zinc-finger transcriptional repressors that bind to a six base sequence, CAGGTG, known as the E-box ([@b10-tog-2-2007-049]). It is involved in cell movement during embryogenesis but more importantly when discussing cancer Snail has been implicated in promoting epithelial-mesenchymal transition. It is thought that this phenotype arises from the suppression of E-cadherin by Snail resulting in the loss of contact between neighbouring cells ([@b10-tog-2-2007-049]; [@b19-tog-2-2007-049]). Work by Moody et al. has demonstrated that Snail over-expression can promote recurrence of primary breast tumors in mice and is associated with decreased patient disease free survival time in all patient groups ([@b85-tog-2-2007-049]). While N-Myc and Snail are potential leads to explain how YB-1 is regulated in cancer they are still at this time speculative. Not withstanding, mechanisms that control YB-1 expression remain largely unknown.

Once YB-1 is induced in cancer, it opens the question as to how it is post-translationally regulated. Many transcription factors are indeed regulated by signal transduction. Thus, does YB-1 then take the marching orders RTK's to promote tumor growth and/or resistance to therapy?

How does signal transduction hardwire YB-1 to the genome?
=========================================================

There is no doubt that deregulation of YB-1 results in breast tumor pathogenesis; however, the underlying mechanisms remain unclear. In order to gain more insight into the post-translational regulation of YB-1, our lab took a bioinformatic approach using Motif Scanner to examine putative proteins that may phosphorylate and thus affect the activity of YB-1 ([Table 1](#t1-tog-2-2007-049){ref-type="table"}). As shown in [Table 1](#t1-tog-2-2007-049){ref-type="table"}, many of the proteins that may phosphorylate YB-1 are players in the cancer growth and survival signaling pathways. To focus on how YB-1 may be activated in cancer cells, we will discuss proteins or kinases that are in 1) PI3K/Akt, 2) Ras/MAPK and 3) PKC signaling cascades as these pathways are implicated in the pathogenesis and/or growth regulation of cancer.

PI3K/Akt and YB-1
-----------------

Several components of the PI3K/Akt signaling pathway may be responsible for YB-1 phos-phorylation as shown in [Table 1](#t1-tog-2-2007-049){ref-type="table"}. In the first case, we observed that YB-1 could potentially be phosphorylated by Akt at S102. This became of great interest to us given that the PI3K/Akt pathway is frequently deregulated or constitutively activated in cancer. Activated Akt is often expressed in breast cancer but not normal breast epithelial cells (Kucab et al. 2004). It is also able to transform breast epithelial cells into malignant phenotypes ([@b148-tog-2-2007-049]; [@b146-tog-2-2007-049]). Co-expression of constitutively active Akt1 and mutant polyomavirus T antigen resulted in mammary tumor formation in nude mice ([@b58-tog-2-2007-049]). Exogenous expression of Akt1 enhanced breast cancer cell growth both in monolayer and soft agar assays ([@b2-tog-2-2007-049]), illustrating the ability of Akt to promote tumor progression. Moreover, clinical studies have demonstrated a relationship between Akt and relapse, distant metastasis ([@b100-tog-2-2007-049]; [@b113-tog-2-2007-049]), and poor prognosis ([@b11-tog-2-2007-049]). By screening primary tumor tissue micro-arrays, we found that activated or phosphorylated Akt (p-Akt) was associated with YB-1 in breast cancer ([@b133-tog-2-2007-049]). We then demonstrated that Akt phosphorylates YB-1 at S102 in the CSD, by in vitro GST pull-down experiments and kinase assays ([@b133-tog-2-2007-049]). It was subsequently shown that IGF-1 stimulation led to YB-1(S102) phosphorylation in NIH3T3 cells. Wortmannin, which is a PI3K inhibitor, fully blocked phosphorylation of YB-1 ([@b36-tog-2-2007-049]). More recently, studies in ovarian cancer demonstrate that inhibiting the PI3K/Akt pathways with LY294002 suppresses nuclear translocation in vitro and in mice ([@b8-tog-2-2007-049]). This is in contrast to the study in which YB-1 suppresses Akt-mediated oncogenic transformation of chicken embryo fibroblasts by inhibiting protein synthesis ([@b5-tog-2-2007-049]; [@b6-tog-2-2007-049]). The interpretation of this study would indicate that YB-1 serves as a tumor suppressor gene, which is contrary to the amassed studies indicating that it is rather an oncogene. We suspect that the Akt/YB-1 relationship in avian mesenchymal cells may be different from how this complex works in epithelial cancer cells.

Phosphorylation of YB-1 by Akt could affect this transcription factor by altering nuclear trafficking, DNA binding and/or translation. Inhibition of YB-1(S102) phosphorylation by site directed mutagenesis leads to an attenuation of nuclear translocation ([@b133-tog-2-2007-049]). This could explain why treating ovarian cancer cells with wortmannin or an integrin-linked kinase inhibitor, both of which inhibit activation of Akt, suppressed the nuclear trafficking of YB-1 ([@b8-tog-2-2007-049]). Therefore, nuclear translocation of YB-1 may be controlled by S102 phosphorylation via the PI3K/Akt pathway. YB-1 was shown to have a noncanonical NLS as well as a cytoplasmic retention site (CRS) in the C-terminal domain ([@b6-tog-2-2007-049]). It has been suggested by Jürchott et al. that both the C-terminus and the CSD are involved in YB-1 nuclear shuttling ([@b65-tog-2-2007-049]). It seems reasonable to postulate that S102 in the CSD cooperates with NLS and/or CRS in YB-1 nuclear trafficking. For example, phosphorylation of S102 may induce YB-1 conformational change, which masks the CRS and/or reveals the NLS. A second possibility is that phosphoryation affects DNA binding. Our lab found that while YB-1 bound to the first −2 kB of the *EGFR* promoter, YB-1(A102) was not able to interact with the first −1 kB promoter region ([@b142-tog-2-2007-049]). One may argue that disruption of S102 blocked nuclear translocation of YB-1 thus prevented the binding of YB-1 to the *EGFR* promoter. However upon careful inspection, mutation of S102 to alanine did not completely block nuclear shuttling of YB-1 ([@b133-tog-2-2007-049]). In fact, there was still approximately 50% of YB-1(A102) detected in the nucleus. Abolishment of S102 almost fully prevented Flag:YB-1(A102) from binding to the −1 kb of *EGFR* promoter ([@b142-tog-2-2007-049]). Therefore, we suggest that in addition to nuclear translocation, S102 is also important for enabling YB-1 to bind to DNA. A third possibility is that phosphorylation promotes translation of the oncogenome. It was recently demonstrated that phosphorylation of YB-1 at S102 by Akt prevented YB-1 from binding to the capped 5′ terminus of mRNA thereby promoting the translation of oncogenes such as IGF-1, VEGF and FOS ([@b36-tog-2-2007-049]). It has also been shown that release of YB-1 from mRNA results in nuclear localization ([@b129-tog-2-2007-049]). Thus, YB-1 phosphorylation by Akt allows latent oncogenic transcripts to enter into the translational machinery ([@b36-tog-2-2007-049]). This further disputes the idea that YB-1 is somehow working as a tumor suppressor gene ([@b5-tog-2-2007-049]). Thus, Akt is the first kinase to be shown to regulate YB-1 post-translationally and its consequences have broad implications in the regulation of gene expression in cancer cells.

The motif scanner also predicted that the p85 subunit of PI3K may be able to phosphorylate YB-1 at Tyr197 of the C-terminal domain, possibly to alter the interaction between YB-1 and other proteins. Curiously, Tyr197 is located within the NLS (residue 183--202) ([@b6-tog-2-2007-049]) of YB-1, which raises the question whether YB-1 subcellular localization is affected by phosphorylation at Tyr197 by PI3K. This could explain why the PI3K inhibitor wortmannin completely abolished YB-1 phosphorylation induced by IGF-1 stimulation, whereas mutation of S102 to alanine was not able to fully prevent YB-1 phosphorylation ([@b36-tog-2-2007-049]). The glycogen synthase kinase 3 (GSK3), which is negatively regulated by Akt ([@b30-tog-2-2007-049]), could also potentially phosphorylate YB-1 at Ser21 in the N-terminal domain and affect the transcriptional activity of YB-1 ([Table 1](#t1-tog-2-2007-049){ref-type="table"}). It has been demonstrated by Coles et al. that GSK3β phosphorylated the N-terminus of YB-1, enhancing the ability of YB-1 to repress the vascular endothelial growth factor (VEGF) promoter ([@b25-tog-2-2007-049]). This study also implies the involvement of Akt/GSK3β/YB-1 in tumor angiogenesis. Taken together, it is expected that YB-1 phosphorylation via PI3K/Akt signaling would exert a profound effect on tumor progression.

Ras/MAPK and YB-1
-----------------

Since MAPK/ERK signaling is often elevated in malignancies including breast cancer ([@b122-tog-2-2007-049]; [@b33-tog-2-2007-049]; [@b26-tog-2-2007-049]; [@b31-tog-2-2007-049]), it is motivating to examine whether components of this pathway also regulate YB-1 phosphorylation. Based on the data generated from the Motif Scanner, Shc and Grb2 may phosphorylate YB-1 at several tyrosine residues in the C-terminal domain. These are both adaptor proteins that transduce signals from receptor tyrosine kinases to MAPK. Moreover, the Ser36 residue located in the transactivating N-terminal domain of YB-1 may be a target for the extracellular-signal-regulated kinase 1 (ERK1), which is activated by MAPK in response to growth factor stimulation resulting in cell proliferation and survival ([@b20-tog-2-2007-049], [@b116-tog-2-2007-049]). In a study conducted by Coles et al. it was demonstrated that ERK2 phosphorylated YB-1 in the N-terminal domain, promoting the binding of YB-1 to the VEGF promoter and VEGF expression ([@b25-tog-2-2007-049]). The discovery that ERK2 phosphorylates YB-1 leading to VEGF expression again implies that YB-1 also plays a role in angiogenesis to enhance the micro-environment for tumor growth. Since a recent report overrode the conventional idea that ERK1 and ERK2 play similar functions ([@b140-tog-2-2007-049]), one should validate whether ERK1 also phosphorylates YB-1, leading to VEGF expression.

PKC and YB-1
------------

Many isoforms of protein kinase C (PKC) are predicted by Motif Scanner to regulate YB-1. For example, the classical PKCs (α, β, and γ), whose activation is dependent on Ca^2+^ and diacylglycerol (DAG) ([@b89-tog-2-2007-049]; [@b90-tog-2-2007-049]; [@b149-tog-2-2007-049]; [@b98-tog-2-2007-049]), may phosphorylate Thr62 in the CSD of YB-1. The novel PKCs (δ, ε, θ), which are activated by DAG ([@b89-tog-2-2007-049]; [@b90-tog-2-2007-049]; [@b149-tog-2-2007-049]; [@b98-tog-2-2007-049]), could potentially phosphorylate both the N-terminal domain and the CSD of YB-1. In clinical studies, PKC activities have been shown to be elevated in breast tumor tissues ([@b92-tog-2-2007-049]; [@b45-tog-2-2007-049]). Cell-model based and in vitro studies also demonstrated the relationship between different PKC isoforms and cancers. It has been shown by several studies that increased PKCα is associated with increased motility and invasion of cancer cells while inhibition of PKCα reverses the phenotype ([@b34-tog-2-2007-049]; [@b81-tog-2-2007-049]; [@b99-tog-2-2007-049]; [@b103-tog-2-2007-049]; [@b72-tog-2-2007-049]). PKCβ is suggested to have similar functions as PKCα in cancer cells and is thought to enhance invasion and proliferation of cancer cells ([@b115-tog-2-2007-049]; [@b112-tog-2-2007-049]; [@b143-tog-2-2007-049]; [@b86-tog-2-2007-049]; [@b145-tog-2-2007-049]; [@b63-tog-2-2007-049]; [@b147-tog-2-2007-049]). PKCε also seems to stimulate tumor development and metastasis ([@b3-tog-2-2007-049]). PKCδ, on the other hand, is thought to promote apoptosis and is thus suggested to be a tumor suppressor ([@b79-tog-2-2007-049]; [@b132-tog-2-2007-049]; [@b9-tog-2-2007-049]; [@b14-tog-2-2007-049]; [@b64-tog-2-2007-049]; [@b106-tog-2-2007-049]; [@b1-tog-2-2007-049]; [@b63-tog-2-2007-049]). Although PKCδ is considered a tumor suppressor, it was reported that PKCδ is increased in highly metastatic mammary tumor cell lines ([@b67-tog-2-2007-049]). Interestingly, PKC has been suggested to play a role in the development of estrogen receptor negative (ER(−)) breast cancers. For instance, studies have illustrated that ER(−) breast cancer cell lines such as MDA-MB-231 and MDA-MB-435 express high level of PKCα ([@b15-tog-2-2007-049]; [@b102-tog-2-2007-049]). Moreover, ectopic expression of PKCα caused MCF-7 cells to become ER(−). Importantly, expression of PKCα has been associated with tamoxifen resistance in breast cancer patients ([@b138-tog-2-2007-049]). It should be pointed out that the expression of YB-1 is also associated with ER(−) breast cancers ([@b142-tog-2-2007-049]). Although there is currently no data demonstrating a functional link between PKC and YB-1, it would be intriguing to investigate whether this potential pathway cooperates to alter the ER status and thus increase breast cancer aggressiveness.

In light of the possible phosphoryation sites on YB-1, which could be mediated by the PI3K and MAP kinase pathways, we turn now to the question of how this could impact its function ([Figure 3](#f3-tog-2-2007-049){ref-type="fig"}). Our initial analysis using Motif Scanner revealed that YB-1 could be potentially phosphorylated by Akt at S102, which we went on to show impacted nuclear trafficking ([@b133-tog-2-2007-049]) and more profoundly DNA binding ([@b142-tog-2-2007-049]). It was subsequently reported that S102 phosphorylation also decreases YB-1's ability to act as a transcriptional repressor ([@b36-tog-2-2007-049]). It should be pointed out that PKC and RSK also have the potential to phosphorylate S102 given that they also recognize the RxRxxS/T binding site on proteins. Additionally, we suggest that GSK and ERK1 have the potential to phosphorylate the transactivating domain at S21 and S36 respectively. Finally, the p85 subunit of PI3K could phosphory-late YB-1 at Y197, which is located in the nuclear localization signal therefore cellular trafficking may be affected ([Figure 3](#f3-tog-2-2007-049){ref-type="fig"}).

Is YB-1 a molecular target for cancer therapy?
==============================================

The expression of YB-1 in aggressive types of cancer and the evidence for a role in cell proliferation calls into question its potential as therapeutic target for treatment. There are numerous signal transduction inhibitors (STI's) that could inhibit YB-1 indirectly by blocking the activity of upstream components of, for example, the PI3K pathway ([@b46-tog-2-2007-049]). Akt inhibitors could potentially be used to inhibit YB-1 activity by suppressing S102 phosphorylation. Likewise, preventing Akt activation through phosphoinositide-dependent kinase-1 inhibition (PDK-1) ([@b75-tog-2-2007-049]; [@b27-tog-2-2007-049]) is also a possible way of ultimately suppressing YB-1's function. The PDK-1 inhibitor OSU03012 is an excellent candidate because it inhibits Akt activation (Kucab et al. 2004), does not result in overt toxicity in mice and it can be given orally. Rapamycin, a clinically approved immunosuppressant that inhibits the mammalian target of rapamycin (mTOR) pathway, has recently been shown to reduce the level of phosphorylated YB-1 ([@b36-tog-2-2007-049]) and could therefore suppress the growth promoting effects. Alternatively, direct inhibition of molecules such as YB-1 is now possible either by designing small molecule inhibitors or developing molecular techniques so that they can be used in the clinic. By knocking down YB-1 using siRNA we previously reported that the growth of breast cancer cells is inhibited by 48% ([@b142-tog-2-2007-049]). This is a promising result that could translate into the clinic by silencing YB-1 using either antisense or small interfering RNA's. Clinical trials are underway using antisense to inhibit BCL-2 ([@b21-tog-2-2007-049]; [@b137-tog-2-2007-049]) and clusterin (OGX-011) ([@b84-tog-2-2007-049]; [@b22-tog-2-2007-049]; [@b123-tog-2-2007-049]). There are now many examples of how small interfering RNA's can be used to slow the growth of cancer cells although the clinical development of this technology is still emerging. Recently, (shRNA) short hairpin RNA's targeting survivin were expressed in a lentiviral vector ([@b62-tog-2-2007-049]) and tested in a model of oral squamous cell carcinoma where this target is highly expressed. The loss of survivin using siRNA sensitized the cells to chemotherapy in vitro and inhibited tumor growth in mice ([@b62-tog-2-2007-049]). The first clinical trials using siRNA have begun, however they are not yet being applied in the field of oncology, rather to silence the vascular endothelial growth factor (VEGF) in age-related macular degeneration ([@b48-tog-2-2007-049]). It is therefore within reach that shRNA could be used to treat other diseases such as cancer. We propose therefore that tumor growth could be inhibited by disrupting YB-1 either directly or indirectly using STI's.

Taking a completely different approach, one might consider using the expression of YB-1 to drive the replication of oncolytic viruses as a way of treating cancer. It has been known for some time that YB-1 facilitates the replication of adenoviruses ([@b53-tog-2-2007-049]), which then can be used to kill tumor cells ([@b54-tog-2-2007-049]; [@b43-tog-2-2007-049]). A recent study has shown that infecting drug resistant cells with a YB-1 associated adenovirus can resensitize the cancer cells to chemotherapeutic agents therefore providing opportunities to use combination therapy or "Mutually Synergistic Therapy" ([@b80-tog-2-2007-049]) and prolong the period of time in which some patients may be treated. The expression of YB-1 in basal-like and Her-2 over-expressing breast cancers (submitted data) also provides an excellent opportunity for using oncolytic viruses for therapy. While these gene-based approaches are promising they are still limited by bioavailability, formulations, safety and the expense of making the products. As it is unlikely a single agent will provide us with the most effective treatment it may also be beneficial to assess rational combination therapies like the one described above. As we have discussed here there are multiple opportunities to inhibit the function of YB-1 or even use YB-1 activity to treat cancer.

Concluding Remark
=================

While the role(s) of YB-1 have been extensively studied in cancer, the upstream signaling that regulates this fascinating oncoprotein remains unclear. The Motif Scanner serves as a useful preliminary tool to select putative kinases that may phosphorylate YB-1. To date only the relationship between YB-1 and PI3K/Akt pathway in breast cancer has been established ([@b133-tog-2-2007-049]; [@b36-tog-2-2007-049]). Inhibiting the PI3K/Akt and thus YB-1 has been suggested to be a novel way to treat breast cancer ([@b142-tog-2-2007-049] et al.) as well as many other types of malignancies where this pathway is known to be activated. The evidence presented herein suggested that YB-1 may be regulated by multiple signaling cascades, many of which are hyper-activated in cancer. We therefore envisage that YB-1 hardwires aberrant signaling pathways to induce expression of the oncogenome through transcriptional and well as translational control (overview, [Figure 4](#f4-tog-2-2007-049){ref-type="fig"}). It is now known that YB-1 is expressed in such a wide range of cancers affecting adults and children. Moreover, tumor cells depend upon YB-1 for growth; therefore it could be an excellent molecular target for cancer therapy.
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![**The Structure and Functions of YB-1**. YB-1 is made up of the N-terminal, cold shock (CSD) and C-terminal domains (CTD). These domains have unique functions. The N-terminal is necessary for transactivation whereas the CSD is important for RNA/DNA binding. Most of the characterized protein:protein interactions occur on the CTD. The CSD and CTD also work together to facilitate nuclear trafficking. Cellular trafficking is furthermore regulated by the nuclear localization signal in the C-terminal domain as well as the cytoplasmic retention signal also located in this region of the protein.](tog-2-2007-049f1){#f1-tog-2-2007-049}

![**Putative YB-1 regulatory sites were predicted using CONSITE. (A)** The YB-1 promoter (−2kB) was evaluated for potential regulatory elements using CONSITE against all conserved species where the stringency was set at 90%. **(B)** Alternatively, if only the human database was used, at a 90% cut-off, additional regulatory elements were identified. Finally, evaluating the human database with 100% stringency revealed that N-Myc and Snail binding sites were present.](tog-2-2007-049f2){#f2-tog-2-2007-049}

![**Summary of where signaling pathways potentially phosphorylate YB-1 and how these post-translational changes could impact its function**. In this review, we have highlighted the fact that YB-1 is phosphorylated by Akt at S102 which occurs in the CSD. The consequence of S102 phosphorylation is a change in DNA binding. It also impact YB-1's ability to regulate translation. Because PKC and RSK also have the potential to phosphorylate S102 it is conceivable that they too could alter YB-1's transcriptional and translational capacities. GSK and ERK1 have the potential to phosphorylate YB-1 at S21 and S36 respectively, which could alter YB-1's ability to transactivate. Alternatively the p85 subunit of PI3K could regulate YB-1 by phosphorylating Y197, which resides within the nuclear localization sequence. It is therefore possible that Pi3K could phosphorylate YB-1 and thereby stimulate nuclear trafficking.](tog-2-2007-049f3){#f3-tog-2-2007-049}

![**Schematic of the multiple functions of YB-1 in cancer cells.** Signal transduction is initiated by growth factor such as IGF-1 and cytokines leading to the activation of kinases that could potentially phosphorylate YB-1. It is generally thought that YB-1 is phosphorylated by kinases such as AKT in the cytoplasm leading to nuclear trafficking and DNA binding. The phosphorylation of YB-1 can also alter its role in translation initiation, mRNA splicing and/or transport. In the nucleus, YB-1 binds to multiple genes involved in tumor cell growth by directly binding to inverted CAAT boxes. It also indirectly induces the expression of oncogenes by coupling to other transcription factors such as AP-1 and p53. YB-1 can thus induce the expression of oncogenes through transcriptional as well as translational control.](tog-2-2007-049f4){#f4-tog-2-2007-049}

###### 

Putative proteins that may phosphorylate YB-1 at Ser, Thr, and Tyr suggested by the Motif Scanning Prediction Tool.

  **YB-1 Domain**         **Residue**                                                     **Pitative Regulatory Protein**   **Percentile[^1^](#tfn1-tog-2-2007-049){ref-type="table-fn"}**
  ----------------------- --------------------------------------------------------------- --------------------------------- ----------------------------------------------------------------
  **AP-rich N-Term**      Ser 3                                                           Casein Kinase 2                   3.764
  Thr 7                   DNA PK                                                          0.846                             
                          ATM kinase                                                      4.202                             
  Ser 21                  GSK3 Kinase[^2^](#tfn2-tog-2-2007-049){ref-type="table-fn"}     3.336                             
  Thr 29                  PKC δ                                                           0.806                             
  Ser 32                  Casein Kinase 1                                                 4.315                             
  Ser 36                  Erk 1 Kinase [^2^](#tfn2-tog-2-2007-049){ref-type="table-fn"}   3.248                             
  **cold shock domain**   Thr 62                                                          PKC δ                             2.773
                          PKC α/β/γ                                                       4.452                             
                          PKC θ                                                           4.964                             
  Thr 80                  DNA PK                                                          2.965                             
  Thr 89                  Calmodulin dependent kinase2                                    2.786                             
                          PKC θ                                                           4.964                             
  Ser 102                 Akt kinase[^3^](#tfn3-tog-2-2007-049){ref-type="table-fn"}      2.703                             
  Ser 102                 PKC ε                                                           3.527                             
  Glu 107                 PDZ (nNOS)class 3                                               1.003                             
  Thr 108                 DNAPK                                                           3.529                             
                          Casein kinase 2                                                 3.764                             
  **c-term**              Tyr 162                                                         Grb2 SH2                          2.274
  Ser 167                 ATM kinase                                                      4.812                             
  Ser 176                 14-3-3                                                          1.029                             
                          Casein kinase 2                                                 2.023                             
  Tyr 197                 Shc PTB                                                         3.945                             
                          p85 SH2                                                         4.884                             
  Tyr 208                 Abl SH2                                                         0.292                             
                          Crk SH2                                                         1.209                             
                          Itk SH2                                                         2.124                             
                          Nck SH2                                                         2.092                             
                          Grb2 SH2                                                        2.983                             
  Thr 271                 DNA PK                                                          1.761                             
                          ATM kinase                                                      2.342                             
  Tyr 287                 Shc PTB                                                         3.170                             
  Ser 314                 Casein kinase 2                                                 2.775                             

Given by the Motif scanning prediction tool, the percentile tells how the protein ranks by comparing with all vertebrate proteins in Swiss-Prot, the sequence surrounding that site, and the solvent accessibility at that position.

Phosphorylation of YB-1 by GSK^3^ and ERK^2^ has been demonstrated by [@b25-tog-2-2007-049].

Phosphorylation of YB-1 by Akt has been shown by [@b133-tog-2-2007-049] and [@b36-tog-2-2007-049].
